Comparative effectiveness will boost R&D: Woodcock
May 15, 2009
6:16 pm
The FDA’s director of drugs, Janet Woodcock, believes the movement toward comparative effectiveness research will lead to a more internationally harmonized drug development process.
Brand teams have had huge success with traditional DTC advertising. Slowly but surely, new media channels were adopted, but the fundamentals remained the same: reach as many people as possible with a broad message necessary to drive NRx or TRx.
Heading up the biggest brand in online health has its benefits. “When I tell people I work at WebMD, they smile and tell me how the site has helped them,” says Wayne Gattinella. “That makes me feel really good.”
Is the hourly-rate model used by the majority of pharmaceutical marketers and advertisers antiquated? Mike Myers provides some alternatives to the current system including the notion that clients should pay for ideas, instead of the time that it took to create them
Clashes often occur between the creative and analytic departments when the time comes to run tests that confirm which ideas best achieve a promotional objective. Robert Egert and Louis Winokur explain the challenges faced by both groups
The policies stemming from DC will be important in determining what pharma products and medical devices are accepted and successful and which do not meet the standard set by the policymakers. Robert Schooling reports